Santhera Pharmaceuticals AG (SANN.SW) Plunges on European Eye Drug Rejection
1/18/2013 7:37:43 AM
More...
|
Santhera Pharmaceuticals AG (SANN.SW) and Ipsen Renegotiate Fipamezole Licensing Agreement
1/24/2012 6:02:17 AM
More...
|
Santhera Pharmaceuticals AG (SANN.SW) and Ipsen Enter into Licensing Agreement for Fipamezole for the Treatment of Dyskinesia in Parkinson's Disease; Upfront Payment of 13 Million Euros With Another Milestones of Up To 128 Million Euros
9/3/2010 7:26:17 AM
More...
|
Santhera Pharmaceuticals AG (SANN.SW) Eyes Approval of Lead Drug, Catena in First Half of 2011
6/16/2010 7:00:01 AM
More...
|
Santhera Pharmaceuticals AG (SANN.SW)'s MICONOS Trial with Catena/Sovrima in Friedreich's Ataxia Misses Phase 3 Primary Endpoint
5/20/2010 7:33:26 AM
More...
|
Biovail Pharmaceuticals, Inc., Santhera Pharmaceuticals AG Strike Parkinson's Drug Deal; Santhera Could Pay up to $184 Million
8/24/2009 6:32:40 AM
More...
|
Santhera Pharmaceuticals AG Cuts Jobs to Slow Cash Burn
7/7/2009 9:09:58 AM
More...
|
ugichem GmbH to Enter Into Research Collaboration With Santhera Pharmaceuticals AG
3/23/2009 12:17:06 PM
More...
|
Committee for Medicinal Products for Human Use (CHMP) Confirms Original Opinion on Santhera Pharmaceuticals AG's SNT-MC17/Idebenone for Treatment of Friedreich's Ataxia
11/19/2008 2:33:36 PM
More...
|
Santhera Pharmaceuticals AG Enrolls Last Patient in Pivotal US Phase III with SNT-MC17/Idebenone in Friedreich's Ataxia
11/11/2008 4:36:27 PM
More...
|
|